1. Aurobindo Pharma
stock logo

67% Buy

Aurobindo Pharma Share Price

AUROPHARMA

₹1,088.45-₹20.20 (-1.82%) Past Year
₹1,086.00₹1,127.95
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • F&O (Option chain)

  • More

Company overview

About

arrow

Market cap

Market Cap Switch₹63,776 Cr

Open

₹1,110.10

Close

₹1,108.65

Circuit range

₹1,219.50 - ₹997.80

Day range

₹1,086.00 - ₹1,127.95

Year range

₹536.45 - ₹1,177.10

Volume

12,16,798

Avg. traded

₹1,100.66

Revenue (12m)

₹27,895 Cr

Aurobindo Pharma

Founded in 1986 by PV Ramprasad Reddy and K Nityananda Reddy, Aurobindo Pharma is one the largest pharmaceutical companies in India. Its operations began in 1988 with a single unit producing semi-synthetic penicillin (SSP) in Puducherry. The company went public in 1992 and was listed on the stock exchanges in 1995.

The market capitalisation of Aurobindo Pharma Limited is over ₹63,800 crore as of December 28, 2023. Aurobindo Pharma share price has gained over 14% in three years.

Business operations

Aurobindo Pharma specialises in producing semi-synthetic penicillin and has a strong presence in various essential medical areas such as cephalosporins, antivirals, cardiovascular and gastroenterology. It is the leading provider of semi-synthetic penicillin medications. The company's product range covers formulations like those for cardiovascular, gastroenterology, antiretrovirals and anti-infectives.

Notable formulations include trandolapril, captopril, and benazepril hydrochloride, among others. It also manufactures active pharmaceutical ingredients and organic intermediates like desmethyl azithromycin, methenamine and benzimidazole.

Aurobindo Pharma operates 11 units for APIs/intermediates and 15 units (10 in India, three in the USA, one in Brazil and one in Portugal) for formulations, strategically designed to cater to both established and emerging market needs.

In the United States, Aurobindo Pharma operates across oral medications, injectables, over-the-counter and branded oncology segments. It has submitted 774 ANDAs (abbreviated new drug applications) and received 565 final approvals as of March 31, 2023.

In Europe, Aurobindo Pharma has established its presence in 10 countries with fully equipped pharmacies, hospitals, and sales infrastructure for tenders.

Its business model heavily relies on its input. A total of ₹1,411.5 crore was allocated towards research and development (R&D). This initiative led to the submission of 774 Abbreviated New Drug Applications (ANDAs), 276 Drug Master Files (DMFs) and 813 filed patent applications. The company filed 4,359 formulation dossiers and 3,718 API (Active Pharmaceutical Ingredient) product submissions in various markets outside the USA.

As an integrated pharmaceutical company, Aurobindo Pharma ranks among India's top pharmaceutical firms in terms of combined revenues. Exporting to over 150 countries globally, approximately 90% of its revenue comes from international ventures, serving esteemed multinational clientele.

Aurobindo Pharma’s facilities have approvals from major regulatory bodies across the world such as USFDA, EU GMP, UK MHRA, Health Canada, WHO and Brazil ANVISA.

Aurobindo Pharma operates five research centres spanning 16,000 square meters, along with two additional R&D centres in the USA. The company has a team of over 1,560 in-house scientists and analysts for product development.

Financial highlights

Aurobindo Pharma Limited's revenue from operations for FY23 stood at ₹24,855 crore, up 6% from ₹23,456 crore in FY22. The company recorded a PAT (profit after tax) of ₹1,928 crore in FY23 against ₹2,647 crore in FY22. In FY23, the earnings before interest, taxes, depreciation and amortisation (EBITDA) decreased to ₹3,758 crore from the previous year's ₹4,387 crore. The company's earnings per share (EPS) stood at ₹32.9 in FY23 compared to ₹45.19 in the previous financial year.

Read more

Aurobindo Pharma Key indicators

arrow

52 week high

₹1,177.10

52 week low

₹536.45

P/E ratio

23.04

P/B ratio

2.19

ROE

7.02%

ROCE

8.44%

Dividend yield

0.28%

Debt/Equity ratio

0.23

EPS

21

Learn more

Investment checklist: (3/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

67%

Hold

20%

Sell

13%

This analysis is based on the reviews of 24 experts in the last 7 days

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

16.8%

Net profit margin

9.55%

ROE

7.02%

ROA

4.57%

ROCE

8.44%

Learn more

Aurobindo Pharma Shareholder returns

arrow

1 day

-1.82%

1 week

-3.13%

1 month

+4.19%

3 months

-0.58%

1 year

+93.81%

3 years

+18.93%

5 years

+40.09%

Revenue statement

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Cash flow

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Balance sheet

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Aurobindo Pharma Share Price history

arrow
DayOpenCloseDay’s change
Fri, Apr 12 2024
₹1,110.10
₹1,088.45
-1.99%
Wed, Apr 10 2024
₹1,132.00
₹1,108.65
-2.11%
Tue, Apr 9 2024
₹1,124.00
₹1,131.95
+0.70%
Mon, Apr 8 2024
₹1,129.90
₹1,120.25
-0.86%
Fri, Apr 5 2024
₹1,123.00
₹1,123.70
+0.06%
Thu, Apr 4 2024
₹1,137.10
₹1,123.60
-1.20%
Wed, Apr 3 2024
₹1,103.00
₹1,137.65
+3.05%
Tue, Apr 2 2024
₹1,114.55
₹1,101.45
-1.19%

Shareholding info

arrow

Promoters (51.83%)

Mutual Funds (17.83%)

Retail and other (6.87%)

Foreign institutions-FII (18.01%)

Other domestic institutions (5.46%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹1.5/share

    Ex date 20 Feb 2024

    expand tab
  • Dividend • ₹3/share

    Ex date 20 Nov 2023

    expand tab
  • Dividend • ₹3/share

    Ex date 17 Feb 2023

    expand tab
  • Dividend • ₹4.5/share

    Ex date 06 Jun 2022

    expand tab
  • Dividend • ₹1.5/share

    Ex date 18 Feb 2022

    expand tab
  • Dividend • ₹1.5/share

    Ex date 17 Nov 2021

    expand tab

Learn more

Frequently asked questions